ALDX

Business Context and Reporting Period

Aldeyra Therapeutics, Inc. (ALDX) is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. This Form 10-Q covers the quarterly period ended June 30, 2026. The Company's primary late-stage product candidate is reproxalap for dry eye disease, which is currently subject to an exclusive option agreement with AbbVie. As of June 30, 2026, the Company had 60,326,421 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Debt Repayment: On April 1, 2026, the Company repaid in full the outstanding $15.0 million principal balance under its Loan and Security Agreement with Hercules Capital, Inc. Consequently, interest expense decreased significantly, and the Company currently has no debt obligations.
• Expense Reduction: Research and development (R&D) expenses decreased by approximately 63% year-over-year for the six months ended June 30, 2026 ($5.9 million vs. $15.9 million in 2025). This was driven by reduced external clinical development costs and drug product manufacturing costs.
• Liquidity Position: Cash and cash equivalents decreased by approximately $25.0 million during the six months ended June 30, 2026, primarily due to the debt repayment and operating losses, though the burn rate has slowed compared to the prior year.
• Deferred Revenue: The Company recorded $6.0 million in deferred collaboration revenue related to the AbbVie Option Agreement, classified as a current liability.

Outlook, Risks, and Management Commentary

• Reproxalap Regulatory Status: The Company received a Complete Response Letter (CRL) from the FDA on March 17, 2026, regarding the reproxalap New Drug Application (NDA). The FDA cited a lack of substantial evidence of efficacy. The Company is engaging in Type A and Type D meetings with the FDA to discuss potential resubmission strategies. No assurance can be given that the FDA will ultimately grant approval.
• AbbVie Option: As of August 6, 2026, AbbVie has not exercised its exclusive option to collaborate on reproxalap. The option period is restricted to ten business days following FDA approval of the NDA. If exercised, the Company could receive a $100 million upfront payment (net of prior fees) and up to $300 million in milestones.
• Liquidity Outlook: Management believes current cash resources ($45.1 million) are sufficient to fund projected operating expenses into the second half of 2028, excluding potential licensing revenue. However, the Company will likely need to secure additional funding in the future to continue development and commercialization efforts.
• Legal Proceedings: A putative securities class action lawsuit was filed on March 30, 2026, alleging violations of securities laws regarding statements made about the reproxalap NDA. The Company cannot predict the outcome or potential losses.
• Operational Risks: The Company relies heavily on third-party manufacturers and CROs. It also faces risks related to the FDA's "radical transparency" policy regarding the public release of CRLs, which could impact investor confidence and stock price volatility.

Investor Verification Checklist

• Regulatory Pathway: Verify the outcome of the upcoming Type D meeting with the FDA regarding the reproxalap NDA resubmission and the specific data requirements for approval.
• AbbVie Option Exercise: Monitor for any announcement regarding AbbVie's decision to exercise the option, which is contingent on FDA approval.
• Cash Runway: Confirm the Company's burn rate and the sufficiency of the $45.1 million cash balance to fund operations through the projected 2028 timeline without additional financing.
• Legal Exposure: Track the status of the securities class action lawsuit filed in March 2026 and any potential settlement or dismissal.
• Manufacturing Compliance: Review the status of the FDA's recent inspection of the third-party manufacturer for reproxalap (closed as Voluntary Action Indicated) to ensure no future supply disruptions.